Exxon Mobil stock is highly leveraged to the price of oil. So, if oil prices recover in 2019, XOM's share price should should spike higher. Read More
Forecasts
Our AT&T Stock Prediction In 2019 (Buy or Sell?)
As AT&T grapples with the multi-media revolution, can this legacy telecom light a fire under its lagging stock price? Read More
-
-
Rho is a gauge that helps you evaluate options contracts and their exposure to the risk of interest rate fluctuations. Here's how it works. Read More
-
We frequently advise investors to know their risk tolerance. Here's a time-tested measure for understanding the potential volatility in your portfolio. Read More
-
The rising incidence of hacking dominates the front pages. We examine cybersecurity firm Bravatek to see if it's a growth play or just another risky fad stock. Read More
-
Nike is one of the most recognizable brands in the world. The company has faced some stiff competition lately. Will it remain Number One? Read More
-
This global colossus dominates the thriving management consulting industry. But as the pace of change accelerates, can the company stay on top? Read More
-
There's a trio of economic trends that will drive the market higher this year. Shareholders of these three companies stand to benefit the most. Read More
-
An examination of Therapix Biosciences, its rivals, and a prediction for this micro-cap biotech stock in 2019. Will Therapix prove a winner or loser in the race to develop cannabis-based drugs? Read More
-
An examination of Supreme Cannabis stock, its rivals, whether it's overpriced or underpriced, and a prediction for the stock in 2019. Read More
-
Amazon's new headquarters near Washington DC could elevate Jeff Bezos’ legacy to something far greater than being remembered as the guy that wrecked retail. Read More
-
Our review of clinical-stage medical cannabis companies continues, with a fledgling biotech that's generating especially keen interest on Wall Street. Is Cara a future bonanza... or short-term fad? Read More
-
We examine a clinical-stage biotech making medicines from cannabis. Is the stock a hot prospect or is all the hype just a smokescreen for a fundamentally weak investment? Read More
-
We spotlight Intec Pharma, its rivals, and whether the stock is overpriced or underpriced. Is this Israel-based biotech on the verge of launching blockbuster new drugs? Read More
-
Marie Kondo's famous book on cleaning out your closet contains some helpful hints that are easily applied to your portfolio. Use this mid-winter bounce to clean out your stocks. Read More
-
An examination of this popular biotech stock, its rivals, whether it's overpriced or underpriced, and a prediction for its prospects in 2019. Read More
-
Zynerba Pharmaceuticals is a fledgling, small-cap maker of cannabis-based drugs. The stock has attracted considerable media interest, but is it too risky? We sift through the hype to examine the fundamentals. Read More